Form 4: Heron Therapeutics CEO Craig Collard Reports Stock Transactions
SEC Form 4 Filing
Heron Therapeutics CEO Craig Collard reports the vesting and subsequent disposal of restricted stock units.
Summary
- On April 19, 2024, Craig Collard, CEO of Heron Therapeutics, reported transactions involving restricted stock units.
- A total of 13,797 restricted stock units vested and were subsequently disposed of.
- These units represent a contingent right to receive one share of common stock each.
- Following the reported transactions, Collard directly owns 262,793 shares of common stock.
- Collard also directly owns 206,953 derivative securities in the form of restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by a company executive, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects the routine vesting and disposal of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Date of grant for the restricted stock units, which vest in 16 equal quarterly installments beginning one quarter after this date. |
| 04/19/2024 | Date of the transaction: vesting and disposal of 13,797 restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.